摘要
目的探讨莫西沙星联合阿米卡星治疗耐多药肺结核的疗效。方法选择2008年1月～2010年1月我院收住的80例MDR-TB患者作为研究对象。所有患者在治疗中均全程加用常规保肝药物。观察组:6ADL2EM/18DL2EM(6个月A、D、L、E、M,18个月D、L、E、M);对照组:6ADL2EV/18DL2EV(6个月A、D、L、E、V,18个月D、L、E、V),比较两组的痰菌阴转率、疗效以及空洞闭合率、不良反应。结果两组随着治疗时间延长,其痰菌阴转率明显升高,且观察组痰菌阴转率升高较对照组显著,差异有统计学意义(P<0.05)。观察组咳嗽、咯痰症状改善时间显著短于对照组,而观察组治疗后的有效率及空洞闭合率明显高于对照组,差异有统计学意义(P<0.05)。结论莫西沙星联合阿米卡星治疗耐多药肺结核疗效确切,安全性好,值得推广和应用。
Objective To investigate the efficacy of moxifloxacin combined with amikacin in treatment of multidrug-resis tant tuberculosis. Methods From January 2008 to January 2010, gO cases of MDR-TB patients were selected as research subjects. All patients in the treatment of the whole added to conventional bepatoprotective drug. Observation group： 6ADL2EM/18DL2EM （meaning 6 A and D, L, E, M, 18 D, L, E, M）; control group： 6ADL2EW18DL2EV （meaning 6 A, D, L, E, V, 18 D, L, E, V）. Results With the extension of treatment time, the sputum conversion rate was significantly in creased, and the observation group sputum conversion rate increased more than the control group, the difference was statis tically significant （P 〈 0.05）. Cough, expectoration symptoms improved significantly shorter than the control group, while the observation group treatment efficiency and cavity closure rate were significantly higher, and the difference were statistically significant （P 〈 0.05）. Conclusion Moxifloxacin combined with amikaein in treatment of multidrug-resistant tuberculosis has good efficacy and safety, is worthy of promotion and application.
出处
《中国现代医生》
2012年第24期52-53,共2页
China Modern Doctor
关键词
耐多药肺结核
莫西沙星
阿米卡星
Multidrug-resistant tuberculosis
Moxifloxacin
Amikacin
